Search

Your search keyword '"Schreuder, A.H."' showing total 2 results
Start Over Author "Schreuder, A.H."
2 results on '"Schreuder, A.H."'

1. Phase-based vascular input function: Improved quantitative DCE-MRI of atherosclerotic plaques

Author

Hoof, R.H.M. van, Hermeling, E., Truijman, M.T.B., Oostenbrugge, R.J. van, Daemen, J.W.H., Geest, R.J. van der, Orshoven, N.P. van, Schreuder, A.H., Backes, W.H., Daemen, M.J.A.P., Wildberger, J.E., Kooi, M.E., Amsterdam Cardiovascular Sciences, Pathology, RS: CARIM - R3 - Vascular biology, MUMC+: HZC Med Staf Spec Klinische Neurofys (9), Surgery, Promovendi CD, Beeldvorming, MUMC+: MA AIOS Neurologie (9), Klinische Neurowetenschappen, MUMC+: MA Med Staf Spec Neurologie (9), Vascular Surgery, MUMC+: MA Med Staf Spec Vaatchirurgie (9), MUMC+: MA Vaatchirurgie CVC (3), MUMC+: DA BV Klinisch Fysicus (9), Pathologie, and MUMC+: DA Beeldvorming (5)

Subjects
viruses, carotid atherosclerosis, virus diseases, vascular input function, pharmacokinetic modeling, biochemical phenomena, metabolism, and nutrition, dynamic contrast-enhanced MRI
Abstract

Purpose: Quantitative pharmacokinetic modeling of dynamic contrast-enhanced (DCE)-MRI can be used to assess atherosclerotic plaque microvasculature, which is an important marker of plaque vulnerability. Purpose of the present study was (1) to compare magnitude-versus phase-based vascular input functions (m-VIF vs ph-VIF) used in pharmacokinetic modeling and (2) to perform model calculations and flow phantom experiments to gain more insight into the differences between m-VIF and ph-VIF. Methods: Population averaged m-VIF and ph-VIFs were acquired from 11 patients with carotid plaques and used for pharmacokinetic analysis in another 17 patients. Simulations, using the Bloch equations and the MRI scan geometry, and flow phantom experiments were performed to determine the effect of local blood velocity on the magnitude and phase signal enhancement. Results: Simulations and flow phantom experiments revealed that flow within the lumen can lead to severe underestimation of m-VIF, while this is not the case for the ph-VIF. In line, the peak concentration of the m-VIF is significantly lower than ph-VIF (p 0.93 (p 0.58 (p

Published
2015

2. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial

Author

Westendorp, W.F., Vermeij, J.D., Zock, E., Hooijenga, I.J., Kruyt, N.D., Bosboom, H.J., Kwa, V.I.H., Weisfelt, M., Remmers, M.J., Houten, R. ten, Schreuder, A.H., Vermeer, S.E., Dijk, E.J. van, Dippel, D.W., Dijkgraaf, M.G., Spanjaard, L., Vermeulen, M, Poll, T. van der, Prins, J.M., Vermeij, F.H., Roos, Y.B., Kleyweg, R.P., Kerkhoff, H., Brouwer, M.C.T., Zwinderman, A.H., Beek, D. van de, Nederkoorn, P.J., Westendorp, W.F., Vermeij, J.D., Zock, E., Hooijenga, I.J., Kruyt, N.D., Bosboom, H.J., Kwa, V.I.H., Weisfelt, M., Remmers, M.J., Houten, R. ten, Schreuder, A.H., Vermeer, S.E., Dijk, E.J. van, Dippel, D.W., Dijkgraaf, M.G., Spanjaard, L., Vermeulen, M, Poll, T. van der, Prins, J.M., Vermeij, F.H., Roos, Y.B., Kleyweg, R.P., Kerkhoff, H., Brouwer, M.C.T., Zwinderman, A.H., Beek, D. van de, and Nederkoorn, P.J.

Abstract

Item does not contain fulltext, BACKGROUND: In adults with acute stroke, infections occur commonly and are associated with an unfavourable functional outcome. In the Preventive Antibiotics in Stroke Study (PASS) we aimed to establish whether or not preventive antimicrobial therapy with a third-generation cephalosporin, ceftriaxone, improves functional outcome in patients with acute stroke. METHODS: In this multicentre, randomised, open-label trial with masked endpoint assessment, patients with acute stroke were randomly assigned to intravenous ceftriaxone at a dose of 2 g, given every 24 h intravenously for 4 days, in addition to stroke unit care, or standard stroke unit care without preventive antimicrobial therapy; assignments were made within 24 h after symptom onset. The primary endpoint was functional outcome at 3 months, defined according to the modified Rankin Scale and analysed by intention to treat. The primary analysis was by ordinal regression of the primary outcome. Secondary outcomes included death, infection rates, antimicrobial use, and length of hospital stay. Participants and caregivers were aware of treatment allocation but assessors of outcome were masked to group assignment. This trial is registered with controlled-trials.com, number ISRCTN66140176. FINDINGS: Between July 6, 2010, and March 23, 2014, a total of 2550 patients from 30 sites in the Netherlands, including academic and non-academic medical centres, were randomly assigned to the two treatment groups: 1275 patients to ceftriaxone and 1275 patients to standard treatment (control group). 12 patients (seven in the ceftriaxone group and five in the control group) withdrew consent immediately after randomisation, leaving 2538 patients available for the intention-to-treat-analysis (1268 in the ceftriaxone group and 1270 in the control group). 2514 (99%) of 2538 patients (1257 in each group) completed 3-month follow-up. Preventive ceftriaxone did not affect the distribution of functional outcome scores on the modified Rankin

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results